Loading...

Brilliant Violet 605™ anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_BV605_CD45_Antibody_FC_080113.jpg
C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 605™ (filled histogram) or rat IgG2b, κ Brilliant Violet 605™ isotype control (open histogram).
  • 30-F11_BV605_CD45_Antibody_FC_080113.jpg
    C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 605™ (filled histogram) or rat IgG2b, κ Brilliant Violet 605™ isotype control (open histogram).
See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
103139 125 µL 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103155 50 µg 210€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103140 500 µL 348€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining with µg, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For flow cytometric staining with µl, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kakizaki M, Watanabe R 2017. Neuropathology. 10.1111/neup.12386. PubMed
  2. Pavelko K, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01532. PubMed
  3. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  4. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  5. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  6. Chen JC et al. 2018. Cell systems. 7(1):92-103 . PubMed
  7. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  8. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  9. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  10. Freemerman AJ, et al. 2019. J Immunol. 202:1265. PubMed
  11. Gkountela S et al. 2019. Cell. 176(1-2):98-112 . PubMed
  12. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  13. Bennion BG, et al. 2019. J Virol. 93. PubMed
  14. Zhang Y, et al. 2019. Nat Commun. 10:3667. PubMed
  15. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  16. Dalmas E et al. 2017. Immunity. 47(5):928-942 . PubMed
  17. Kuhn NF et al. 2019. Cancer cell. 35(3):473-488 . PubMed
  18. Di Mitri D, et al. 2019. Cell Rep. 28:2156. PubMed
  19. Grizotte–Lake M, et al. 2018. Immunity. 49:1103. PubMed
  20. McDonald LT, et al. 2017. PLoS One. 12:e0180724. PubMed
  21. Bhattacharya A, et al. 2018. Neuropsychopharmacology. 43:2586. PubMed
  22. Castillo–Azofeifa D, et al. 2019. EMBO J. 38:e99984. PubMed
  23. Lloyd AF, et al. 2019. Nat Neurosci. 1.643055556. PubMed
  24. Shao Y, et al. 2019. Stem Cells. 37:1331. PubMed
  25. Gyoneva S, et al. 2019. Life Sci Alliance. 2:e201900453. PubMed
  26. Huai W, et al. 2019. J Exp Med. 216:772. PubMed
  27. Wagner JA, et al. 2020. Cell Rep. 31:107720. PubMed
  28. Hong JP, et al. 2020. Cell Reports Medicine. 1(3):100035. PubMed
  29. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  30. Chen M, et al. 2019. Cell Stem Cell. 25:501. PubMed
  31. Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed
  32. Berrien–Elliott MM, et al. 2020. Immunity. 51(3):479-490. PubMed
  33. Chen YG, et al. 2020. Molecular Cell. 76(1):96-109. PubMed
  34. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  35. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  36. Shao Y, et al. 2019. Diabetes. 68:2131. PubMed
  37. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  38. AR P, et al. 2016. Circ Res. 118: 400-409. PubMed
  39. Payne K, et al. 2016. J Leukoc Biol. 100: 625 - 635. PubMed
  40. Cortez-Toledo O, et al. 2017. PLoS One. 12(2):e0171268. PubMed
  41. Kuhn NF, et al. 2020. Nat Commun. 4.74375. PubMed
  42. Zou C, et al. 2020. Cell Rep. 33:108447. PubMed
  43. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  44. Boyd DF, et al. 2020. Nature. 587:466. PubMed
  45. Myers DR, et al. 2020. Front Immunol. 11:576310. PubMed
  46. Wong P, et al. 2021. STAR Protoc. 2:100262. PubMed
  47. Marinaccio C, et al. 2021. Cancer Discovery. 11(6):1398-1410. PubMed
  48. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
  49. Becattini S, et al. 2021. Cell Host Microbe. 29(3):378-393.e5. PubMed
  50. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  51. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  52. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  53. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  54. Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed
  55. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  56. Lu SX, et al. 2021. Cell. . PubMed
  57. Israelow B, et al. 2020. bioRxiv. . PubMed
  58. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  59. Gao Y, et al. 2020. Nat Cell Biol. 1064:22. PubMed
  60. Lee J, et al. 2020. Gut Microbes. 1:. PubMed
  61. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  62. Perez-Cruz M, et al. 2021. PLoS One. e0236216:16. PubMed
  63. Molgora M, et al. 2020. Cell. 182:886. PubMed
  64. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  65. Nording H, et al. 2021. Nat Commun. 12:3352. PubMed
  66. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  67. Reddy A, et al. 2020. Cell. 183:62. PubMed
  68. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  69. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  70. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  71. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  72. Dando SJ, et al. 2021. Invest Ophthalmol Vis Sci. 62:10. PubMed
  73. Liang J, et al. 2021. Cancer Manag Res. 13:6977. PubMed
  74. Skibba ME, et al. 2021. Respir Res. 22:315. PubMed
  75. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  76. Lee A, et al. 2022. Nat Commun. 13:549. PubMed
  77. Khamissi FZ, et al. 2022. Sci Adv. 8:eabm5900. PubMed
  78. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  79. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  80. Sharma D, et al. 2022. Commun Biol. 5:479. PubMed
  81. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  82. Li H, et al. 2022. iScience. 25:104481. PubMed
  83. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  84. Terp MG, et al. 2021. Mol Oncol. 15:3299. PubMed
  85. Celik H, et al. 2021. Cancer Discov. 11:3126. PubMed
  86. Ren J, et al. 2021. JCI Insight. 6:. PubMed
  87. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  88. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  89. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  90. Ganguly K, et al. 2022. Front Immunol. 13:930449. PubMed
  91. Zhu Y, et al. 2022. Nat Commun. 13:4282. PubMed
  92. Olson CA, et al. 2021. Cell Host Microbe. 29:1378. PubMed
  93. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  94. Bunting MD, et al. 2022. Sci Adv. 8:eabk3327. PubMed
  95. Baik JE, et al. 2022. Clin Transl Med. 12:e758. PubMed
  96. Michalaki C, et al. 2022. Curr Protoc. 2:e505. PubMed
  97. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  98. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  99. Wolf KG, et al. 2022. JVS Vasc Sci. 3:336. PubMed
  100. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  101. Krishnamurty AT, et al. 2022. Nature. 611:148. PubMed
  102. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  103. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  104. Zhu X, et al. 2023. Front Immunol. 14:1114802. PubMed
  105. Hettwer J, et al. 2022. Cardiovasc Res. 118:2778. PubMed
  106. Zhao L, et al. 2022. Oncogene. 41:4200. PubMed
  107. Roweth HG, et al. 2022. Sci Adv. 8:eabo5224. PubMed
  108. Wang C, et al. 2023. iScience. 26:106272. PubMed
  109. Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed
  110. Santharam MA, et al. 2023. Int J Mol Sci. 24:. PubMed
  111. De C, et al. 2023. JCI Insight. 8:. PubMed
  112. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  113. Mulcrone PL, et al. 2023. Sci Rep. 13:8436. PubMed
  114. Prior JT, et al. 2023. NPJ Vaccines. 8:80. PubMed
  115. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
RRID
AB_2562341 (BioLegend Cat. No. 103139)
AB_2650656 (BioLegend Cat. No. 103155)
AB_2562342 (BioLegend Cat. No. 103140)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 3    Revision Date: 01/11/2017

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account